Gary Altwerger
Yale University
CancerInternal medicineOncologyExome sequencingChemistryIn vitroImmunohistochemistryIn vivoChemotherapyUterine serous carcinomaHER2/neuEndometrial cancerAntibody-drug conjugateTrastuzumabPrimary tumorOvarian cancerCarboplatinGynecologyAntibody-dependent cell-mediated cytotoxicityCancer researchMedicineBiology
61Publications
12H-index
387Citations
Publications 60
Newest
Source
Source
#1Shari DamastH-Index: 14
Last. Elena RatnerH-Index: 28
view all 0 authors...
Source
#1Stefania Bellone (Yale University)H-Index: 29
#2Dana M. Roque (UMB: University of Maryland, Baltimore)H-Index: 18
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 33 authors...
Source
#1Jungmin Choi (Yale University)H-Index: 18
#2Aranzazu Manzano (Yale University)H-Index: 7
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 44 authors...
Uterine leiomyosarcomas (uLMS) are aggressive tumors arising from the smooth muscle layer of the uterus. We analyzed 83 uLMS sample genetics, including 56 from Yale and 27 from The Cancer Genome Atlas (TCGA). Among them, a total of 55 Yale samples including two patient-derived xenografts (PDXs) and 27 TCGA samples have whole-exome sequencing (WES) data; 10 Yale and 27 TCGA samples have RNA-sequencing (RNA-Seq) data; and 11 Yale and 10 TCGA samples have whole-genome sequencing (WGS) data. We foun...
Source
#1Shari Damast (Yale University)H-Index: 14
#2Christopher J TienH-Index: 4
Last. Elena RatnerH-Index: 28
view all 0 authors...
#1Emily M. Webster (Yale University)H-Index: 1
#2Ghanshyam S. Yadav (BCM: Baylor College of Medicine)H-Index: 5
Last. Gary Altwerger (Yale University)H-Index: 12
view all 18 authors...
Research within a gynecologic oncology population has lagged behind the uptake in use of medical cannabis for symptom control. This study seeks to evaluate patient experience with prescribed medical cannabis obtained through licensed dispensaries in women with gynecologic malignancies. A 43-item survey exploring patient experience with medical cannabis was administered to women with gynecologic malignancies who used medical cannabis prescribed by a gynecologic oncologist. Thirty-six eligible pat...
Source
#1Joan Tymon-Rosario (Yale University)H-Index: 6
#2Paola Manara (Yale University)H-Index: 8
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 18 authors...
Source
#1Elena Bonazzoli (Yale University)H-Index: 16
#2Stefania Bellone (Yale University)H-Index: 29
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 20 authors...
Abstract Objective Whole-exome-sequencing (WES) studies reported c-MYC gene-amplification and HUWE1 gene deletion/mutations in a significant number of cervical-cancer-patients (CC) suggesting HUWE1/c-MYC pathway as potential therapeutic target. We investigated HUWE1/c-MYC expression in fresh-frozen-CC and the activity of the novel BET inhibitor GS-626510 (Gilead-Science-Inc) against primary WES CC-cultures and CC-xenografts. Methods HUWE1 and c-MYC expression were evaluated by qRT-PCR in 23 CC i...
Source
#1Emanuele Perrone (Yale University)H-Index: 12
#2Paola Manara (Yale University)H-Index: 8
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 22 authors...
Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody-drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell-surface antigen-2 (Trop-2) - a cell-surface glycoprotein highly expressed in many epithelial tumors - and delivers the active metabolite of irinotecan SN-38 to Trop-2-positive tumor cells. We evaluated Trop-2 expression in endometrial endometrioid carcinoma (EC) tissues and the activity of SG against primary poorly differentiat...
6 CitationsSource